Transcranial Direct Current Stimulation in Substance Use Disorders

Nakamura-Palacios, Ester Miyuki; Ronchete, Christiane Furlan; Felippe, Luna Vasconcelos; Ferreira, Leonardo Villaverde Buback; Anders, Quézia Silva; Rodrigues, Lívia Carla de Melo

doi:10.1007/978-3-030-76136-3_27

Cited by 2 publications

(2 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The utilization of animal models in elucidating the effects of brain stimulation has been particularly instrumental in deciphering the underlying molecular mechanisms that influence underlying brain regions. This foundational understanding is crucial in bolstering clinical studies that focus on neuromodulation in the treatment of neuropsychiatric conditions, such as SUDs [57]. For example, findings from experimental animal studies offer potential insights into the applicability of brain stimulation methods for modulating abnormal plasticity in SUDs [58][59][60].…”

Section: Knowledge From Preclinical Studiesmentioning

confidence: 99%

Neuromodulation (Brain Stimulation) Technologies for Treatment of Substance Use Disorders

Souki,

Soleimani,

Hanlon

et al. 2024

Preprint

View full text Add to dashboard Cite

This chapter traces the historical development of brain stimulation technologies and their methodological parameters for treating substance use disorders (SUDs). These methods include Transcranial Electrical Stimulation (tES), Transcranial Magnetic Stimulation (TMS), Deep Brain Stimulation (DBS), and Transcranial Focused Ultrasound Stimulation (tFUS). The application of magnetic stimulation in modulating addictive behaviors dates back to the development of TMS for cigarette smoking around 2003 and later for cocaine use disorders around 2007. The development of electrical devices paralleled the early use of direct current stimulation in electrical medicine, starting around 2008 for alcohol and nicotine use disorders. Throughout the twentieth century, electrical medicine evolved, with increasingly sophisticated electronics allowing for new technologies utilizing complex waveforms (first transcranial alternating current stimulation (tACS) trial in SUD in 2020). Additionally, the first report investigating the effects of low-intensity tFUS neuromodulation for SUDs was published in 2023, demonstrating safety and significant decreases in cravings for all substances. The first systematic reviews on the application of tES and TMS for SUDs were conducted in 2012, indicating that these noninvasive brain stimulation technologies could be promising options in addiction treatment. More than 80% of previous brain stimulation studies targeted the dorsolateral prefrontal cortex, intending to modulate regions associated with pathophysiological excitability. However, there was significant variability between and within studies in terms of experimental design and individual responses to brain stimulation for addiction and meta-analyses reported small to medium effect sizes for the effectiveness of these technologies in SUDs. By the end of 2018, only 84 published tES/TMS trials were conducted in the field of SUDs. By the end of 2022, this number had increased to 198 studies. Following a decade of rapid growth, the United States Food and Drug Administration (FDA) cleared TMS for smoking cessation (FDA: K200957) in 2020. Since then, there has been an accelerating pace of new clinical trials using novel tools and protocols of non-invasive neuromodulation for SUDs, and the list of devices and indications receiving CE marking in Europe is growing. Over the last decade, systematic exploration of the dose-response and individual variability in brain stimulation methods has suggested new approaches to optimize responses. In recent years, there has been rapid growth and expansion of non-invasive neuromodulations as circuit-based interventional tools in SUD research. In 2023, trials emerged using fMRI-informed individualized brain stimulation for SUDs, utilizing fMRI data to inform brain stimulation parameters. This chapter introduces different types of brain stimulation methods for SUDs, emphasizing the unique role of tES and TMS in altering the broader trajectory of brain stimulation research for SUDs. The methodological parameter space and incremental approach have been foundational in outstanding tES/TMS studies, serving as a scientific anchor for the broader (re)discovery of non-invasive brain stimulation in this field.

show abstract

Section: Knowledge From Preclinical Studiesmentioning

confidence: 99%

Neuromodulation (Brain Stimulation) Technologies for Treatment of Substance Use Disorders

Souki,

Soleimani,

Hanlon

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…These molecular mechanisms also mediate cortical changes induced by NIBS (Pelletier and Cicchetti, 2014;Chervyakov et al, 2015;Yamada and Sumiyoshi, 2021). Animal studies have shown that tDCS enhances the expression of NMDA and BDNF (Brain-Derived Neurotrophic Factor) and involves AMPA (α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid) receptor modulation and GAP-43 (cortical growth-associated protein) expression, possibly related to improving cognitive performance (Wu et al, 2017;de Souza Custodio et al, 2018;Martins et al, 2019;Nakamura-Palacios et al, 2021). However, Serrano et al (2022) observed a reduction of serum BDNF which was correlated with the improvement of WM and other cognitive tasks induced by homebased anodal tDCS in patients with fibromyalgia.…”

Section: Neurochemical and Molecular Mechanisms Underlying Fm-theta A...mentioning

confidence: 99%

Would frontal midline theta indicate cognitive changes induced by non-invasive brain stimulation? A mini review

Nakamura-Palacios

Júnior

Anders

et al. 2023

Front. Hum. Neurosci.

Self Cite

View full text Add to dashboard Cite

To the best of our knowledge, neurophysiological markers indicating changes induced by non-invasive brain stimulation (NIBS) on cognitive performance, especially one of the most investigated under these procedures, working memory (WM), are little known. Here, we will briefly introduce frontal midline theta (FM-theta) oscillation (4–8 Hz) as a possible indicator for NIBS effects on WM processing. Electrophysiological recordings of FM-theta oscillation seem to originate in the medial frontal cortex and the anterior cingulate cortex, but they may be driven more subcortically. FM-theta has been acknowledged to occur during memory and emotion processing, and it has been related to WM and sustained attention. It mainly occurs in the frontal region during a delay period, in which specific information previously shown is no longer perceived and must be manipulated to allow a later (delayed) response and observed in posterior regions during information maintenance. Most NIBS studies investigating effects on cognitive performance have used n-back tasks that mix manipulation and maintenance processes. Thus, if considering FM-theta as a potential neurophysiological indicator for NIBS effects on different WM components, adequate cognitive tasks should be considered to better address the complexity of WM processing. Future research should also evaluate the potential use of FM-theta as an index of the therapeutic effects of NIBS intervention on neuropsychiatric disorders, especially those involving the ventral medial prefrontal cortex and cognitive dysfunctions.

show abstract

Transcranial Direct Current Stimulation in Substance Use Disorders

Cited by 2 publications

References 150 publications

Neuromodulation (Brain Stimulation) Technologies for Treatment of Substance Use Disorders

Neuromodulation (Brain Stimulation) Technologies for Treatment of Substance Use Disorders

Would frontal midline theta indicate cognitive changes induced by non-invasive brain stimulation? A mini review

Contact Info

Product

Resources

About